Response time, DOR, PFS, and OS in patients with R/R MZL receiving parsaclisib treatment. (A) Cumulative time to response curves, and (B) Kaplan-Meier estimates of DOR, (C) PFS, and (D) OS in the DG (blue) and all treated patients (red) (cohort 2). All response assessments were by IRC.